What is the market's earnings forecast for RenovoRx next quarter?

What is RenovoRx's gross profit margin?

What does RenovoRx do and what are its main business segments?

What guidance did RenovoRx's management provide for the next earnings period?

What were the key takeaways from RenovoRx’s earnings call?

Did RenovoRx beat or miss consensus estimates last quarter?

What factors drove the changes in RenovoRx's revenue and profit?

What were the key takeaways from RenovoRx's earnings call?

- **Commercial Growth**: Year-to-date revenue of $900,000 with 14 approved centers, up from 5 in 2023, and 24 centers requesting quotes. U.S. market opportunity estimated at $400 million annually.
- **Clinical Progress**: Phase III TIGeR-PaC trial randomized 95 patients (61 events), with enrollment expected to complete in early 2026. Post-marketing registry study launched with three sites.
- **Financial Stability**: $10.1 million in cash as of Q3 2025, sufficient to fund operations into mid-2026. COGS reduced through U.S.-based manufacturing.
- **Strategic Focus**: Prioritizing U.S. market expansion with targeted sales hires, while maintaining fiscal discipline.

**【Management Opening Remarks】**
- Dr. Ramtin Agah highlighted the adoption of the TAMP platform across 14 leading cancer centers, including academic and community hospitals, and the launch of TAMP Workshops for peer-to-peer training. He emphasized the platform's ability to deliver targeted chemotherapy with reduced systemic toxicity.

**【CEO Commentary】**
- Shaun Bagai reported year-to-date revenue of $900,000 through Q3 2025, up from $500,000 in 2024, with 14 centers approved to purchase RenovoCath (up from 5 in 2023). Five centers have already placed repeat orders, and 24 centers have requested quotes. The company hired a Senior Director of Sales and two regional managers, with plans to add a marketing director in 2026. The U.S. market opportunity for RenovoCath is estimated at $400 million annually, with potential expansion into other tumor types.

**【CFO Financial Commentary】**
- Ron Kocak reported Q3 2025 revenue of $266,000, with total R&D and SG&A expenses of $3.4 million. The company ended the quarter with $10.1 million in cash, sufficient to fund operations into mid-2026. COGS have been reduced through a U.S.-based contract manufacturer, and the device has a two-year shelf life.

**【Clinical Updates】**
- Lisa Gentry announced the launch of a post-marketing registry study with three initial sites, generating real-world data on safety and efficacy. The phase III TIGeR-PaC trial, which compares intra-arterial gemcitabine to IV chemotherapy, has randomized 95 patients (61 events) and is expected to complete enrollment in early 2026, with final data in 2027. The Data Monitoring Committee expressed confidence in the trial's potential positive outcome.

**【Q&A Highlights】**
- **International Expansion**: CEO Shaun Bagai stated the company will focus on the U.S. market due to favorable reimbursement and large addressable population, but will monitor international interest.
- **Supply Chain**: The device is manufactured in the U.S. with a 2-year shelf life, allowing for rapid scaling. COGS have been reduced through a strategic partnership.
- **Sales Pipeline**: 24 centers have requested quotes, with dozens more expressing interest. The sales cycle varies from several weeks to months, but can be accelerated with local representation.
- **Clinical Momentum**: The registry study and TIGeR-PaC trial are generating evidence to support broader adoption of TAMP as the fourth pillar of cancer treatment.

RenovoRx Inc (RNXT) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

RNXT

RNXT fundamentals

You can ask Aime